F19. 1








Fig. 2







Counts per gram of tissue (x105)








2








Fig. 9




Fig. 10

Angiogenic Regulators Within Platelets 开 j =


- Positive	C Negative
VEGF-A	PF-4
VEGF-C	Thrombospondin
bFGF	NK1, NK2, NK3 fragments of HGF
HGF	
	TGF-beta-1
Angiopoietin-1	
	Plasminogen (angiostatin)
PDGF	High molecular weight kininogen (domain 5)
EGF	Fibronection (45 kD fragment)
IGF-1	
IGF BP-3	EGF (fragment)
Vitronection	Alpha-2 antiplasmin (fragment)
Fibronectin	Beta-thromboglobulin
Fibrinogen	
Heparanase	Endostatin

Folkman, Browder, & Palmblad, Thrombosis & Haemostasis 86: 23, 2001.

BDNF (brain derived neurotrophic factor) Sphingosine-1 PO₄ Y. Yatomi, et al., Blood 86: 193, 1995.

Donovan et al., Development 127: 4531, 2000.

Matrigel 100μ l (50 ng 125 l VEGF)



Non-angiogenic vs angiogenic human liposarcoma in nude mice. Luciferase luminescence at 133 days.





Fig IF

Platelet and Plasma Protein Expression Protocol using SELDI-TOF



-ig 15

Protein expression maps of extracts of platelets and plasma

Fig 16





Fig 17

Protein expression maps of extracts of platelets and plasma from SCID mice bearing non-angiogenic and angiogenic human liposarcomas, (30 days after tumor implantation).



Protein expression maps of extracts of platelets and plasma from SCID mice bearing non-angiogenic and angiogenic human liposarcomas, (30 days after tumor implantation).




Fig 18

Non-angiogenic human liposarcoma (< 1 mm.)

Time course of sequestration of **bFGF** in platelets of tumor-bearing mice.
Only molecular weight of 1820 Daltons included.








Fig 19



















Protein expression maps of extracts of platelets and plasma from SCID mice bearing non-angiogenic and angiogenic human liposarcomas, (30 days after tumor implantation).

